Supplementary Figures from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Year: 2023
Type: supplementary-materials
Abstract: Fig. S1. Screening of oncology drugs to identify agents with immuno-stimulatory properties. Fig. S2. Expression of Ccl5, Cxcl9 and Cxcl10 was normalized to ribosomal 18s RNA and is shown as fold change compared to DMSO treated LKR (set at 1). Fig. S3. Treatment regimen of mice receiving i.p. anti-CD4/CD8 and romidepsin. Fig. S4. Percentage of CD4 or CD8 in DAPI- (viable) peripheral blood of mice receiving anti- CD8 or anti-CD4 at 300mug, as indicated. Fig. S5. PD-L1 expression. Cell surface expression of PD-L1 determined by FACS in viable LKR, 393P (393) and 344SQ (344) cells after 24h treatment with 30nM romidepsin or IFNgamma as indicated. UT: untreated cells. Fig. S6. (A) Impact of romidepsin (n=6) and anti-PD-1 (n=7) treatment on LKR tumor growth for 47 days. Fig. S7. 129 mice were inoculated s.c. with 106 344SQ (344) following which they were treated with 2mg/kg romidepsin on days 14,16,18, with or without 300μg/mouse anti-PD-1 antibody on days 15,17,19 as indicated. Fig. S8. (A) Heatmap analysis using conventional red-green scale of microarray results of LKR cells after IFNgamma and/or romidepsin treatment for genes increased after combined vs. single treatments. Fig. S9. (A) 129 mice with day 14 tumors were untreated (UT) or treated with romidepsin on days 14 and 16 and anti-PD-1 antibody on days 15 and 17 (RP) after which FACS was used to determine CD4 (CD3+CD4+) and CD8 (CD3+CD8+) percentages in total viable cells (day 19). Fig. S10. 129 mice were inoculated s.c. with 106 LKR cells. Effect of romidepsin (Rom) treatment (2mg/kg on days 14,16,18) on tumor growth over indicated time periods is shown. Fig. S11. 129 mice were i.p. injected with 2mg/kg romidepsin twice. 48h after the last injection, MDSC cells (CD11b+ Gr1 + Ly- 6G +) from blood of mice (n=3) were analyzed by FACS. Fig. S12. Western blot analysis of LKR cells treated with Romidepsin (Rom) and/ or IFNgamma as indicated. STAT1 levels are shown in whole cell lysates and β-actin levels are indicated as controls
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361909486